CLINICAL TRIALS PROFILE FOR ALISERTIB
✉ Email this page to a colleague
Clinical Trials for Alisertib
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00500903 ↗ | A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors | Completed | Millennium Pharmaceuticals, Inc. | Phase 1 | To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of MLN8237 when given by mouth (PO) for a minimum of 7 and a maximum of 21 consecutive days, followed by a 14-day recovery period. |
| NCT00651664 ↗ | A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies | Completed | Millennium Pharmaceuticals, Inc. | Phase 1 | This is a multicenter, dose escalation, phase 1 study of MLN8237 in adult participants with advanced malignancies (excluding those with primary bone marrow involvement, such as leukemias and multiple myeloma). |
| NCT00697346 ↗ | Study of MLN8237 in Participants With Advanced Hematological Malignancies | Completed | Millennium Pharmaceuticals, Inc. | Phase 1 | This is an open-label, multicenter, phase 1 study of MLN8237 in participants with advanced hematological malignancies for whom there are limited standard treatment options. |
| NCT00807495 ↗ | Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma | Completed | Millennium Pharmaceuticals, Inc. | Phase 2 | The purpose of this study is to evaluate the anti-tumor activity of alisertib (MLN8237) in participants with relapsed or refractory non-hodgkin's lymphoma. |
| NCT00830518 ↗ | A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome | Completed | Millennium Pharmaceuticals, Inc. | Phase 2 | This is an open-label, multicenter, phase 2 study of alisertib (MLN8237) in participants with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). |
| NCT00853307 ↗ | MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma | Completed | Millennium Pharmaceuticals, Inc. | Phase 2 | The purpose of this study is to evaluate the anti-tumour activity of alisertib (MLN8237) in the treatment of participants with platinum-refractory or platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinomas. |
| NCT00962091 ↗ | Study of MLN8237 in Participants With Advanced Solid Tumors | Completed | Millennium Pharmaceuticals, Inc. | Phase 1 | The purposes of this study were to estimate the relative (Rel) bioavailability (BA) of an oral solution (OS) formulation of alisertib in reference to a powder-in-capsule (PIC) formulation, to characterize the effect of food on the single-dose pharmacokinetics (PK) of alisertib OS and enteric-coated tablets (ECT), to characterize the multiple-dose safety, tolerability, and steady-state PK of alisertib administered as an OS, and to characterize the multiple-dose safety and tolerability of alisertib administered as an ECT. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Alisertib
Condition Name
Clinical Trial Locations for Alisertib
Trials by Country
Clinical Trial Progress for Alisertib
Clinical Trial Phase
Clinical Trial Sponsors for Alisertib
Sponsor Name
